BofA raised the firm’s price target on Akero Therapeutics (AKRO) to $35 from $30 and keeps a Neutral rating on the shares after updating the firm’s model for the “quiet” third quarter. Material updates were “admittedly light,” but the firm thought Akero’s Q3 update was “positive overall,” the firm stated. The firm now forecasts 2025 EPS of ($4.57), versus ($4.36) previously, the analyst noted.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio